Baird lowered the firm’s price target on Genpact to $38 from $44 and keeps an Outperform rating on the shares. The firm said Q3 missed and 2023 guidance reduced on incremental pressure from short-cycle discretionary tech spending. Baird likes the valuation, but the pattern of steadiness has come into question a bit.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on G: